Immune checkpoint inhibitors (anti PD‐1 or anti PD‐L1) plus platinum‐etoposide versus platinum‐etoposide alone for first‐line treatment of extensive small cell lung cancer

Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To evaluate the efficacy and safety of immune checkpoint inhibitors (anti PD-1 or anti PD-L1) plus platinum-etoposide compared with platinum-etoposide alone for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).